Ukr.Biochem.J. 2026; Volume 98, Issue 1, Jan-Feb, pp. 5-19

doi: https://doi.org/10.15407/ubj98.01.005

Cancer stem cells in recurrence and therapy resistance: biological insights and emerging therapeutic strategies

11.02.2026   Uncategorized

Y. Tamilselvi*, P. Velmurugan, K. Sivasubramanian

Centre for Materials Engineering and Regenerative Medicine,
Bharath Institute of Higher Education and Research, India;
*e-mail: pughazselvi@gmail.com

Received: 12 May 2025; Revised: 29 September 2025;
Accepted: 30 January 2026; Available on-line: 23 February 2026

Cancer stem cells (CSCs), a resilient subset of tumor cells, able to evade immune detection and rapidly­ proliferate, are responsible for the metastasis, recurrence, and therapeutic resistance observed across various­ cancers. Recent research has concentrated on understanding the molecular networks that support CSCs immune evasion, self-renewal, and adaptability. Signaling pathways (Wnt, Notch, Hedgehog, JAK-STAT) and surface markers (CD44, CD133, ALDH1) that characterize CSC behaviour are compiled in this review. We highlight the expanding usefulness of omics technologies, such as CRISPR functional genomics, single-cell transcriptomics, and spatial proteomics, in determining vulnerabilities unique to CSCs and guiding­ tailored treatment plans.

Keywords: , , , ,

References:

  1. Agliano A, Calvo A, Box C. The challenge of targeting cancer stem cells to halt metastasis. Semin Cancer Biol. 2017;44:25-42. PubMed, CrossRef
  2. Akhtar S, Hourani S, Therachiyil L, Al-Dhfyan A, Agouni A, Zeidan A, Uddin S, Korashy HM. Epigenetic Regulation of Cancer Stem Cells by the Aryl Hydrocarbon Receptor Pathway. Semin Cancer Biol. 2022;83:177-196. PubMed, CrossRef
  3. Angius A, Scanu AM, Arru C, Muroni MR, Rallo V, Deiana G, Ninniri MC, Carru C, Porcu A, Pira G, Uva P, Cossu-Rocca P, De Miglio MR. Portrait of Cancer Stem Cells on Colorectal Cancer: Molecular Biomarkers, Signaling Pathways and miRNAome. Int J Mol Sci. 2021;22(4):1603. PubMed, PubMedCentral, CrossRef
  4. Dakal TC, Dhabhai B, Pant A, Moar K, Chaudhary K, Yadav V, Ranga V, Sharma NK, Kumar A, Maurya PK, Maciaczyk J, Schmidt-Wolf IGH, Sharma A. Oncogenes and tumor suppressor genes: functions and roles in cancers. MedComm. 2024;5(6):e582. PubMed, PubMedCentral, CrossRef
  5. Bisht S, Nigam M, Kunjwal SS, Sergey P, Mishra AP, Sharifi-Rad J. Cancer Stem Cells: From an Insight into the Basics to Recent Advances and Therapeutic Targeting. Stem Cells Int. 2022;2022:9653244. PubMed, PubMedCentral, CrossRef
  6. Ayob AZ, Ramasamy TS. Cancer stem cells as key drivers of tumour progression. J Biomed Sci. 2018;25(1):20. PubMed, PubMedCentral, CrossRef
  7. Eid RA, Alaa Edeen M, Shedid EM, Kamal ASS, Warda MM, Mamdouh F, Khedr SA, Soltan MA, Jeon HW, Zaki MSA, Kim B. Targeting Cancer Stem Cells as the Key Driver of Carcinogenesis and Therapeutic Resistance. Int J Mol Sci. 2023;24(2):1786. PubMed, PubMedCentral, CrossRef
  8. Limonta P, Chiaramonte R, Casati L. Unveiling the Dynamic Interplay between Cancer Stem Cells and the Tumor Microenvironment in Melanoma: Implications for Novel Therapeutic Strategies. Cancers (Basel). 2024;16(16):2861. PubMed, PubMedCentral, CrossRef
  9. Ganesh K, Massagué J. Targeting metastatic cancer. Nat Med. 2021;27(1):34-44. PubMed, PubMedCentral, CrossRef
  10. Bekaii-Saab T, El-Rayes B. Identifying and targeting cancer stem cells in the treatment of gastric cancer. Cancer. 2017;123(8):1303-1312. PubMed, PubMedCentral, CrossRef
  11. Bocci F, Gearhart-Serna L, Boareto M, Ribeiro M, Ben-Jacob E, Devi GR, Levine H, Onuchic JN, Jolly MK. Toward understanding cancer stem cell heterogeneity in the tumor microenvironment. Proc Natl Acad Sci USA. 2019;116(1):148-157. PubMed, PubMedCentral, CrossRef
  12. Cacho-Díaz B, García-Botello DR, Wegman-Ostrosky T, Reyes-Soto G, Ortiz-Sánchez E, Herrera-Montalvo LA. Tumor microenvironment differences between primary tumor and brain metastases. J Transl Med. 2020;18(1):1. PubMed, PubMedCentral, CrossRef
  13. Cole AJ, Fayomi AP, Anyaeche VI, Bai S, Buckanovich RJ. An evolving paradigm of cancer stem cell hierarchies: therapeutic implications. Theranostics. 2020;10(7):3083-3098. PubMed, PubMedCentral, CrossRef
  14. Franco SS, Szczesna K, Iliou MS, Al-Qahtani M, Mobasheri A, Kobolák J, Dinnyés A. In vitro models of cancer stem cells and clinical applications. BMC Cancer. 2016;16(Suppl 2):738. PubMed, PubMedCentral, CrossRef
  15. Dean L. Tamoxifen Therapy and CYP2D6 Genotype. In: Pratt VM, Scott SA, Pirmohamed M, Esquivel B, Kattman BL , Malheiro AJ. eds. In: Medical Genetics Summaries. Bethesda (MD): National Center for Biotechnology Information (US); 2012. PubMed
  16. Dong Q, Liu X, Cheng K, Sheng J, Kong J, Liu T. Pre-metastatic Niche Formation in Different Organs Induced by Tumor Extracellular Vesicles. Front Cell Dev Biol. 2021;9:733627. PubMed, PubMedCentral, CrossRef
  17. Goenka A, Khan F, Verma B, Sinha P, Dmello CC, Jogalekar MP, Gangadaran P, Ahn BC. Tumor microenvironment signaling and therapeutics in cancer progression. Cancer Commun (Lond). 2023;43(5):525-561. PubMed, PubMedCentral, CrossRef
  18. Eun K, Ham SW, Kim H. Cancer stem cell heterogeneity: origin and new perspectives on CSC targeting. BMB Rep. 2017;50(3):117-125. PubMed, PubMedCentral, CrossRef
  19. Filipów S, Łaczmański Ł. Blood Circulating miRNAs as Cancer Biomarkers for Diagnosis and Surgical Treatment Response. Front Genet. 2019;10:169. PubMed, PubMedCentral, CrossRef
  20. Hanahan D. Hallmarks of Cancer: New Dimensions. Cancer Discov. 2022;12(1):31-46. PubMed, CrossRef
  21. Hapach LA, Mosier JA, Wang W, Reinhart-King CA. Engineered models to parse apart the metastatic cascade. NPJ Precis Oncol. 2019;3:20. PubMed, PubMedCentral, CrossRef
  22. Wu B, Shi X, Jiang M, Liu H. Cross-talk between cancer stem cells and immune cells: potential therapeutic targets in the tumor immune microenvironment. Mol Cancer. 2023;22(1):38. PubMed, PubMedCentral, CrossRef
  23. Lei MML, Lee TKW. Cancer Stem Cells: Emerging Key Players in Immune Evasion of Cancers. Front Cell Dev Biol. 2021;9:692940. PubMed, PubMedCentral, CrossRef
  24. Verona F, Di Bella S, Schirano R, Manfredi C, Angeloro F, Bozzari G, Todaro M, Giannini G, Stassi G, Veschi V. Cancer stem cells and tumor-associated macrophages as mates in tumor progression: mechanisms of crosstalk and advanced bioinformatic tools to dissect their phenotypes and interaction. Front Immunol. 2025;16:1529847. PubMed, PubMedCentral, CrossRef
  25. Lee H, Kim B, Park J, Park S, Yoo G, Yum S, Kang W, Lee JM, Youn H, Youn B. Cancer stem cells: landscape, challenges and emerging therapeutic innovations. Signal Transduct Target Ther. 2025;10(1):248. PubMed, PubMedCentral, CrossRef
  26. Huang T, Song X, Xu D, Tiek D, Goenka A, Wu B, Sastry N, Hu B, Cheng SY. Stem cell programs in cancer initiation, progression, and therapy resistance. Theranostics. 2020;10(19):8721-8743. PubMed, PubMedCentral, CrossRef
  27. Kolling S, Ventre F, Geuna E, Milan M, Pisacane A, Boccaccio C, Sapino A, Montemurro F. “Metastatic Cancer of Unknown Primary” or “Primary Metastatic Cancer”? Front Oncol. 2020;9:1546. PubMed, PubMedCentral, CrossRef
  28. Gao P, Zou D, Zhao A, Yang P. Design and Optimization of the Circulatory Cell-Driven Drug Delivery Platform. Stem Cells Int. 2021;2021:8502021. PubMed, PubMedCentral, CrossRef
  29. Xiao G, Wang X, Xu Z, Liu Y, Jing J. Lung-specific metastasis: the coevolution of tumor cells and lung microenvironment. Mol Cancer. 2025;24(1):118. PubMed, PubMedCentral, CrossRef
  30. Zhao Q, Zong H, Zhu P, Su C, Tang W, Chen Z, Jin S. Crosstalk between colorectal CSCs and immune cells in tumorigenesis, and strategies for targeting colorectal CSCs. Exp Hematol Oncol. 2024;13(1):6. PubMed, PubMedCentral, CrossRef
  31. Bahmad HF, Cheaito K, Chalhoub RM, Hadadeh O, Monzer A, Ballout F, El-Hajj A, Mukherji D, Liu YN, Daoud G, Abou-Kheir W. Sphere-Formation Assay: Three-Dimensional in vitro Culturing of Prostate Cancer Stem/Progenitor Sphere-Forming Cells. Front Oncol. 2018;8:347. PubMed, PubMedCentral, CrossRef
  32. Kumar V, Vashishta M, Kong L, Wu X, Lu JJ, Guha C, Dwarakanath BS. The Role of Notch, Hedgehog, and Wnt Signaling Pathways in the Resistance of Tumors to Anticancer Therapies. Front Cell Dev Biol. 2021;9:650772. PubMed, PubMedCentral, CrossRef
  33. Groenewald W, Lund AH, Gay DM. The Role of WNT Pathway Mutations in Cancer Development and an Overview of Therapeutic Options. Cells. 2023;12(7):990. PubMed, PubMedCentral, CrossRef
  34. Li R, Banjanin B, Schneider RK, Costa IG. Detection of cell markers from single cell RNA-seq with sc2marker. BMC Bioinformatics. 2022;23(1):276. PubMed, PubMedCentral, CrossRef
  35. Song P, Gao Z, Bao Y, Chen L, Huang Y, Liu Y, Dong Q, Wei X. Wnt/β-catenin signaling pathway in carcinogenesis and cancer therapy. J Hematol Oncol. 2024;17(1):46. PubMed, PubMedCentral, CrossRef
  36. You M, Xie Z, Zhang N, Zhang Y, Xiao D, Liu S, Zhuang W, Li L, Tao Y. Signaling pathways in cancer metabolism: mechanisms and therapeutic targets. Signal Transduct Target Ther. 2023;8(1):196. PubMed, PubMedCentral, CrossRef
  37. Meisel CT, Porcheri C, Mitsiadis TA. Cancer Stem Cells, Quo Vadis? The Notch Signaling Pathway in Tumor Initiation and Progression. Cells. 2020;9(8):1879. PubMed, PubMedCentral, CrossRef
  38. Zhou B, Lin W, Long Y, Yang Y, Zhang H, Wu K, Chu Q. Notch signaling pathway: architecture, disease, and therapeutics. Signal Transduct Target Ther. 2022;7(1):95. PubMed, PubMedCentral, CrossRef
  39.  Sachan N, Sharma V, Mutsuddi M, Mukherjee A. Notch signalling: multifaceted role in development and disease. FEBS J. 2024;291(14):3030-3059. PubMed, PubMedCentral, CrossRef
  40. Sari IN, Phi LTH, Jun N, Wijaya YT, Lee S, Kwon HY. Hedgehog Signaling in Cancer: A Prospective Therapeutic Target for Eradicating Cancer Stem Cells. Cells. 2018;7(11):208. PubMed, PubMedCentral, CrossRef
  41. Riobo-Del Galdo NA, Lara Montero Á, Wertheimer EV. Role of Hedgehog Signaling in Breast Cancer: Pathogenesis and Therapeutics. Cells. 2019;8(4):375. PubMed, PubMedCentral, CrossRef
  42. Zhang J, Fan J, Zeng X, Nie M, Luan J, Wang Y, Ju D, Yin K. Hedgehog signaling in gastrointestinal carcinogenesis and the gastrointestinal tumor microenvironment. Acta Pharm Sin B. 2021;11(3):609-620. PubMed, PubMedCentral, CrossRef
  43. Martelli AM, Paganelli F, Truocchio S, Palumbo C, Chiarini F, McCubrey JA. Understanding the Roles of the Hedgehog Signaling Pathway during T-Cell Lymphopoiesis and in T-Cell Acute Lymphoblastic Leukemia (T-ALL). Int J Mol Sci. 2023;24(3):2962. PubMed, PubMedCentral, CrossRef
  44. El-Tanani M, Rabbani SA, Satyam SM, Rangraze IR, Wali AF, El-Tanani Y, Aljabali AAA. Deciphering the Role of Cancer Stem Cells: Drivers of Tumor Evolution, Therapeutic Resistance, and Precision Medicine Strategies. Cancers (Basel). 2025;17(3):382. PubMed, PubMedCentral, CrossRef
  45. Lyu N, Pedersen B, Shklovskaya E, Rizos H, Molloy MP, Wang Y. SERS characterization of colorectal cancer cell surface markers upon anti-EGFR treatment. Exploration (Beijing). 2022;2(3):20210176. PubMed, PubMedCentral, CrossRef
  46. Teoh PL, Saini N. Biomarkers, isolation methods, and therapeutic implications of breast cancer stem cells. Cancer Pathog Ther. 2025;3(5):392-401. PubMed, PubMedCentral, CrossRef
  47. Sarabia-Sánchez MA, Tinajero-Rodríguez JM, Ortiz-Sánchez E, Alvarado-Ortiz E. Cancer Stem Cell markers: Symphonic masters of chemoresistance and immune evasion. Life Sci. 2024;355:123015. PubMed, CrossRef
  48. Varillas JI, Zhang J, Chen K, Barnes II, Liu C, George TJ, Fan ZH. Microfluidic Isolation of Circulating Tumor Cells and Cancer Stem-Like Cells from Patients with Pancreatic Ductal Adenocarcinoma. Theranostics. 2019;9(5):1417-1425. PubMed, PubMedCentral, CrossRef
  49. Radu P, Zurzu M, Paic V, Bratucu M, Garofil D, Tigora A, Georgescu V, Prunoiu V, Pasnicu C, Popa F, Surlin P, Surlin V, Strambu V. CD34-Structure, Functions and Relationship with Cancer Stem Cells. Medicina (Kaunas). 2023;59(5):938. PubMed, PubMedCentral, CrossRef
  50. McLean ME, MacLean MR, Cahill HF, Arun RP, Walker OL, Wasson MD, Fernando W, Venkatesh J, Marcato P. The Expanding Role of Cancer Stem Cell Marker ALDH1A3 in Cancer and Beyond. Cancers (Basel). 2023;15(2):492. PubMed, PubMedCentral, CrossRef
  51. Kim WT, Ryu CJ. Cancer stem cell surface markers on normal stem cells. BMB Rep. 2017;50(6):285-298. PubMed, PubMedCentral, CrossRef
  52. Qiu L, Li H, Fu S, Chen X, Lu L. Surface markers of liver cancer stem cells and innovative targeted-therapy strategies for HCC. Oncol Lett. 2018;15(2):2039-2048. PubMed, PubMedCentral, CrossRef
  53. Prasad S, Ramachandran S, Gupta N, Kaushik I, Srivastava SK. Cancer cells stemness: A doorstep to targeted therapy. Biochim Biophys Acta Mol Basis Dis. 2020;1866(4):165424. PubMed, PubMedCentral, CrossRef
  54. Gires O, Pan M, Schinke H, Canis M, Baeuerle PA. Expression and function of epithelial cell adhesion molecule EpCAM: where are we after 40 years? Cancer Metastasis Rev. 2020;39(3):969-987. PubMed, PubMedCentral, CrossRef
  55. Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet DL, Pulcini C, Kahlmeter G, Kluytmans J, Carmeli Y, Ouellette M, Outterson K, Patel J, Cavaleri M, Cox EM, Houchens CR, Grayson ML, Hansen P, Singh N, Theuretzbacher U, Magrini N; WHO Pathogens Priority List Working Group. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. 2018;18(3):318-327. PubMed, CrossRef
  56. Herreros-Pomares A. Identification, Culture and Targeting of Cancer Stem Cells. Life (Basel). 2022;12(2):184. PubMed, PubMedCentral, CrossRef
  57. Croker H, Whitaker KL, Cooke L, Wardle J. Do social norms affect intended food choice? Prev Med. 2009;49(2-3):190-193. PubMed, CrossRef
  58. 5Ekström S, Andersson N, Lövquist A, Lauber A, Georgelis A, Kull I, Melén E, Bergström A. COVID-19 among young adults in Sweden: self-reported long-term symptoms and associated factors. Scand J Public Health. 2022;50(1):85-93. PubMed, PubMedCentral, CrossRef
  59. Mesbahi Y, Trahair TN, Lock RB, Connerty P. Exploring the Metabolic Landscape of AML: From Haematopoietic Stem Cells to Myeloblasts and Leukaemic Stem Cells. Front Oncol. 2022;12:807266. PubMed, PubMedCentral, CrossRef
  60. Hayashi Y, Nguyen VTT. A narrative review of imatinib-resistant gastrointestinal stromal tumors. Gastrointest Stromal Tumor. 2021;4:6. PubMed, PubMedCentral, CrossRef
  61. Fathy El-Metwaly N, Aref S, Ayed M, Abdel Hamid M, El-Sokkary AMA. CD34+/CD38- Stem Cell Burden Could Predict Chronic Myeloid Leukemia Patients’ Outcome. Asian Pac J Cancer Prev. 2021;22(10):3237-3243. PubMed, PubMedCentral, CrossRef
  62. Botezatu C, Costea DO, Nichilò M, Lazar AM, Andraș D, Radu MI, Mastalier B. The Five-Year Outcomes of Breast Cancer Surgical Management at the Colentina Surgical Clinic, Bucharest, Romania: A Descriptive Retrospective Analysis Between 2019 and 2023. Life (Basel). 2025;15(1):92. PubMed, PubMedCentral, CrossRef
  63. Kushwaha PP, Verma S, Kumar S, Gupta S. Role of prostate cancer stem-like cells in the development of antiandrogen resistance. Cancer Drug Resist. 2022;5(2):459-471. PubMed, PubMedCentral, CrossRef
  64. Parmiani G. Melanoma Cancer Stem Cells: Markers and Functions. Cancers (Basel). 2016;8(3):34. PubMed, PubMedCentral, CrossRef
  65. Wang J, Wu Y, Gao W, Li F, Bo Y, Zhu M, Fu R, Liu Q, Wen S, Wang B. Identification and characterization of CD133+CD44+ cancer stem cells from human laryngeal squamous cell carcinoma cell lines. J Cancer. 2017;8(3):497-506. PubMed, PubMedCentral, CrossRef
  66. Gupta P, Rizvi SZ, Lal N, Gupta V, Srivastav AN, Musa O. Expression of CD44 and CD133 stem cell markers in squamous cell carcinoma of esophagus. Indian J Pathol Microbiol. 2021;64(3):472-478. PubMed, CrossRef
  67. Natarajan K, Xie Y, Baer MR, Ross DD. Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance. Biochem Pharmacol. 2012;83(8):1084-1103. PubMed, PubMedCentral, CrossRef
  68. Bhatia S, Wang P, Toh A, Thompson EW. New Insights Into the Role of Phenotypic Plasticity and EMT in Driving Cancer Progression. Front Mol Biosci. 2020;7:71. PubMed, PubMedCentral, CrossRef
  69. Garg P, Malhotra J, Kulkarni P, Horne D, Salgia R, Singhal SS. Emerging Therapeutic Strategies to Overcome Drug Resistance in Cancer Cells. Cancers (Basel). 2024;16(13):2478. PubMed, PubMedCentral, CrossRef
  70. Doustmihan A, Fathi M, Mazloomi M, Salemi A, Hamblin MR, Jahanban-Esfahlan R. Molecular targets, therapeutic agents and multitasking nanoparticles to deal with cancer stem cells: A narrative review. J Control Release. 2023;363:57-83. PubMed, CrossRef
  71. Aramini B, Masciale V, Grisendi G, Bertolini F, Maur M, Guaitoli G, Chrystel I, Morandi U, Stella F, Dominici M, Haider KH. Dissecting Tumor Growth: The Role of Cancer Stem Cells in Drug Resistance and Recurrence. Cancers (Basel). 2022;14(4):976. PubMed, PubMedCentral, CrossRef
  72. Liu YP, Zheng CC, Huang YN, He ML, Xu WW, Li B. Molecular mechanisms of chemo- and radiotherapy resistance and the potential implications for cancer treatment. MedComm. 2021;2(3):315-340. PubMed, PubMedCentral, CrossRef
  73. Manni W, Min W. Signaling pathways in the regulation of cancer stem cells and associated targeted therapy. MedComm. 2022;3(4):e176. PubMed, PubMedCentral, CrossRef
  74. Zeng Z, Fu M, Hu Y, Wei Y, Wei X, Luo M. Regulation and signaling pathways in cancer stem cells: implications for targeted therapy for cancer. Mol Cancer. 2023;22(1):172. PubMed, PubMedCentral, CrossRef
  75. Chen Y, Chen L, Yu J, Ghia EM, Choi MY, Zhang L, Zhang S, Sanchez-Lopez E, Widhopf GF 2nd, Messer K, Rassenti LZ, Jamieson C, Kipps TJ. Cirmtuzumab blocks Wnt5a/ROR1 stimulation of NF-κB to repress autocrine STAT3 activation in chronic lymphocytic leukemia. Blood. 2019;134(13):1084-1094. PubMed, PubMedCentral, CrossRef
  76. Choi MY, Widhopf GF 2nd, Ghia EM, Kidwell RL, Hasan MK, Yu J, Rassenti LZ, Chen L, Chen Y, Pittman E, Pu M, Messer K, Prussak CE, Castro JE, Jamieson C, Kipps TJ. Phase I Trial: Cirmtuzumab Inhibits ROR1 Signaling and Stemness Signatures in Patients with Chronic Lymphocytic Leukemia. Cell Stem Cell. 2018;22(6):951-959.e3. PubMed, PubMedCentral, CrossRef
  77. Cui X, Liu R, Duan L, Cao D, Zhang Q, Zhang A. CAR-T therapy: Prospects in targeting cancer stem cells. J Cell Mol Med. 2021;25(21):9891-9904. PubMed, PubMedCentral, CrossRef
  78. Li B, Kong X, Post H, Raaijmakers L, Peeper DS, Altelaar M. Proteomics and Phosphoproteomics Profiling of Drug-Addicted BRAFi-Resistant Melanoma Cells. J Proteome Res. 2021;20(9):4381-4392. PubMed, PubMedCentral, CrossRef
  79. Jung J, Seol HS, Chang S. The Generation and Application of Patient-Derived Xenograft Model for Cancer Research. Cancer Res Treat. 2018;50(1):1-10. PubMed, PubMedCentral, CrossRef
  80. Hadiloo K, Mostanadi P, Asadzadeh A, Taremi S, Esmaeilzadeh A. Targeting cancer stem cells with CAR-based immunotherapy: biology, evidence, and future directions. Cancer Cell Int. 2025;25(1):289. PubMed, PubMedCentral, CrossRef
  81. Masoumi J, Jafarzadeh A, Abdolalizadeh J, Khan H, Philippe J, Mirzaei H, Mirzaei HR. Cancer stem cell-targeted chimeric antigen receptor (CAR)-T cell therapy: Challenges and prospects. Acta Pharm Sin B. 2021;11(7):1721-1739. PubMed, PubMedCentral, CrossRef
  82. Scioli MG, Storti G, D’Amico F, Gentile P, Fabbri G, Cervelli V, Orlandi A. The Role of Breast Cancer Stem Cells as a Prognostic Marker and a Target to Improve the Efficacy of Breast Cancer Therapy. Cancers (Basel). 2019;11(7):1021. PubMed, PubMedCentral, CrossRef
Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License.